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192Objective: In standard ventricular restraint therapy, a single level of restraint is applied to the entire ventricular
surface. We showed previously that at high restraint levels, cardiac tamponade develops because of the thin-
walled right ventricle, even while the left ventricle remains unaffected. We now hypothesize that applying re-
straint exclusively to the left ventricle permits higher levels of restraint, resulting in increased benefit to the
left ventricle.
Methods: The acute effect of restraint applied to the left ventricle alonewas analyzed in healthy and cardiomyo-
pathic sheep hearts. Restraint therapy was applied by fluid-filled epicardial balloons placed solely around the left
ventricle. Restraint level was defined by the measured balloon luminal pressure at end diastole. At incrementally
higher restraint levels (0, 3, 5, 8, 10, 12, and 14 mm Hg), transmural myocardial left ventricular pressure
(Ptm ¼ Left ventricle pressureBalloon pressure) and indices of myocardial oxygen consumption were mea-
sured in healthy sheep (n ¼ 5) and in sheep with heart failure (n ¼ 6).
Results: Increasing restraint from 0 to 14 mmHg decreased transmural myocardial pressure by 48.8% (P .02)
and the left ventricle tension-time index by 39.1% (P .01), and the pressure–volume area decreased by 58.4%
(P  .01). Similarly, stroke work decreased by 57.9% (P  .03). Systemic hemodynamics were unchanged.
There was no difference in the trend for all indices between animals that were healthy and those with heart fail-
ure.
Conclusions: We showed previously that, with standard restraint, right ventricle tamponade develops at high
restraint levels, limiting restraint therapy. We now show that restraint applied to the left ventricle alone permits
increased restraint levels, without causing right ventricle or left ventricle tamponade, for greater therapeutic ben-
efit. We conclude that partial left ventricle restraint may be more effective than standard restraint. (J Thorac Car-
diovasc Surg 2013;146:192-7)Ventricular restraint therapy is a nontransplant surgical treat-
ment for heart failure duringwhich the entire ventricular sur-
face is wrapped with a prosthetic material.1,2 The intent is to
provide diastolic support to the failing heart and to prevent
adverse ventricular remodeling. Current restraint devices
have led to improvements in left ventricle (LV) volume,
ejection fraction, and sphericity index, correlating with
reverse remodeling. Currently, however, clinical restraint is
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The Journal of Thoracic and Cardiovascular Surgadjustable,3-14 which may limit overall therapeutic
efficacy. To address this, we previously developed an
adjustable and measurable method of applying restraint
using a fluid-filled, half-ellipsoidal balloon applied to the en-
tire epicardial surface.15,16 We defined the restraint level as
the balloon luminal pressure measured at end diastole.
Using an ovine model of LV failure, a restraint level of 3
mm Hg was found to be the optimal level that reduced
myocardial wall stress acutely, and engendered reverse
remodeling associated without causing associated cardiac
tamponade.16 We found that restraint levels of 5 mm Hg or
greater were associated with a significant increase in central
venous pressure (CVP) and a reduction inmean arterial pres-
sure (MAP), consistentwith global tamponade physiology.16
Previously, it was unclear whether tamponade was sec-
ondary to impaired LV versus right ventricle (RV) filling.
To address this question, our laboratory recently reported
that ventricular restraint therapy affects the RVand LV quite
differently.17 By increasing incrementally the restraint levels
up to and beyond levels that cause tamponade, and by mea-
suring separately the effects on each ventricle, we were able
to analyze the effect of restraint on the LV versus the RV.We
found that as restraint increased to higher levels, the LV con-
tinued to benefit, with improved transmural pressure and
indices of myocardial oxygen consumption (MvO2);ery c July 2013
Abbreviations and Acronyms
CVP ¼ central venous pressure
EDV ¼ end diastolic volume
EF ¼ ejection fraction
ESV ¼ end systolic volume
LGE ¼ late gadolinium enhancement
LV ¼ left ventricle
MAP ¼ mean arterial pressure
MRI ¼ magnetic resonance imaging
MvO2 ¼ myocardial oxygen consumption
Ptm ¼ transmural myocardial pressure
PV ¼ pressure–volume
PVA ¼ pressure–volume area
RV ¼ right ventricle
SW ¼ stroke work
TTI ¼ tension-time index
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pliance.17 The RV, however, behaved very differently. Even
when restraint levelswere increased,we found thatRV trans-
mural pressure remained unchanged whereas RV diastolic
compliance decreased.17 We concluded that the tamponade
seen in standard restraint is caused by alterations that affect
the RVonly while the LV remains completely unaffected.
Because the high restraint levels adversely affect the RV
only, is it possible to apply restraint to the LV alone and, if
so, at much higher therapeutic levels than standard restraint
without causing tamponade? We now hypothesize that re-
straint therapy can be applied solely to the LV with greater
therapeutic efficacy than standard restraint, during which
therapy is applied to both ventricles. We postulate that
such a partial LV restraint permits higher levels of restraint
without tamponade developing. In the experiments reported
herein, healthy and cardiomyopathic sheep hearts were used
to evaluate the immediate effects of partial LV restraint on
systemic and ventricular parameters.
METHODS
Study Overview
All animals were cared for according to the standards set forth in the
Guide for Care and Use of Laboratory Animals.18 published by the Na-
tional Institutes of Health. The protocol was approved by the Institutional
Animal Care and Use Committee at Harvard Medical School.
Eleven adult male sheep (30-50 kg) were used for this study, including
healthy sheep (n ¼ 5) and sheep with heart failure (n ¼ 6). The immediate
effects of partial LV restraint on systemic hemodynamics, transmural pres-
sure, and indices of MvO2 were measured.
Heart Failure Model
Six animals underwent an initial surgery to create heart failure. Eight
weeks after the first surgery, animals underwent cardiac magnetic reso-
nance imaging (MRI; Figure 1). Heart failure was defined as LV ejection
fraction (EF)  40% and a 100% increase in end diastolic volume
(EDV) from baseline.The Journal of Thoracic and CaA postinfarction sheep model of heart failure was utilized.19 This model
includes many of the features of human ischemic dilated cardiomyopathy
and LV remodeling such as increased LV EDVand LVend-systolic volume
(ESV), increased sphericity index, reduced LV EF, and decreased systolic
wall thickening. Six cardiomyopathic sheep were used. A left anterior tho-
racotomywas performed through the fourth intercostal space. The diagonal
branches of the left anterior descending coronary artery and obtuse mar-
ginal branches of the left circumflex coronary artery were identified. Mag-
nesium (2 g intravenously), amiodarone (1.5 mg/kg intravenously), and
lidocaine (3 mg/kg intravenously) were given prior to infarction, along
with an infusion of amiodarone (0.01 mg/kg/minute) and lidocaine
(2 mg/minute) for 60 minutes afterward. The distal aspects of multiple di-
agonal and obtuse marginal branches were ligated using 4-0 polypropylene
sutures. The thoracotomy was closed in layers and the animals recovered.
Postoperatively Buprenorphine (5 mg/kg intramuscularly every 12 hours
for 2 days) was given for pain control; cefazolin (4 mg/kg intramuscularly
every 12 hours for 2 days) was given for antibiotic prophylaxis.
Cardiac Magnetic Resonance
CardiacMRIwas performed in the failure group at 8weeks to confirmde-
velopment of heart failure, as described previously.17 Animals were studied
in a 3.0-T cardia magnetic resonance system (Signa CV/I; GE Healthcare,
Waukesha, Wis) in the lateral decubitus position under general anesthesia
and proper ventilationwith an 8-element phased-array surface coil. A typical
cardiac MRI study consisted of cine steady-state free precession imaging
(repetition time, 3.4 msec; echo time, 1.2 msec; in-plane spatial resolution,
1.63 2 mm) of LV function and late gadolinium enhancement (LGE) imag-
ing (repetition time, 4.8 msec; echo time, 1.3 msec; inversion time, 200-350
msec) formyocardial scar.17 Peripheral pulse gating and breath holdingwere
used asmuch as possible tominimize cardiac and respiratorymotion, respec-
tively.17Whenbreath holdingwas not achieved successfully, a free-breathing
technique was applied using a multiple excitations-per-cycle approach asso-
ciated with reduced views per segment.17 Cine imaging and LGE imaging
wereobtained in8 to14matching short-axis (8mmthickwith 0-mmspacing)
and 3 radial long-axis planes. A previously described segmented inversion–
recovery pulse sequence for LGE was used starting 10 minutes after admin-
istering the 0.2-mmol/kg dose of gadolinium DTPA.20,21
Cine function analysis was performed offline with validated software
(QMASS 7.1; Medis Medical Imaging Systems, Inc, Leiden, The Nether-
lands).20,21 The cardiac phase that demonstrated the the smallest LV cavity
size was defined as end systole; the largest LV cavity size was defined as
end diastole. The endocardial contours of the RV and the LV were traced
manually by the same experienced observer to determine the ventricular
chamber volumes at end diastole and end systole.17 The papillary muscles
were included in the ventricular cavity volume. Given that the basal slice
contained both ventricular and atrial myocardium, the contours were drawn
up to the junction of the atrium and the ventricle, and were joined by
a straight line through the blood pool, as described previously.17 Left ven-
tricle EF was computed using Simpson’s rule: EF calculated as the differ-
ence between EDV and ESV as a percentage of EDV.17
LGE was interpreted as present or absent by the consensus of 2 cardiol-
ogists. Similar to our previous study, LGE was considered present only if
myocardial enhancement was confirmed on both short-axis and matching
long-axis locations.17 With a semiautomatic detection method, using a sig-
nal intensity threshold of>3 standard deviations above a remote reference
region, the myocardial mass of LGE (measured in grams) was then quan-
tified as previously reported.20,21
Left Ventricular Adjustable and Measureable
Ventricular Restraint
The adjustable and measurable restraint device was described previ-
ously by our laboratory.16 Briefly, the device is a half-ellipsoidal balloon
made of medical-grade polyurethane sheets (Polyzen, Inc, Apex, NC).
Each balloon is comprised of 2 1-mm-thick layers. The outer layer of therdiovascular Surgery c Volume 146, Number 1 193
FIGURE 1. Timeline of heart failure creation and terminal study.Myocar-
dial infarction is induced at time 0; cardiac magnetic resonance imaging
(MRI) to document heart failure is performed 8 weeks after myocardial in-
farction; and terminal study, 1 week after cardiac MRI.
FIGURE 2. The partial left ventricular restraint device. A half-ellipsoidal
fluid-filled balloon, which allows for adjustable and measurable restraint
therapy, is positioned on the left ventricle. The restraint level may be ad-
justed by changing the volume of fluid instilled in the balloon. The anterior
and posterior part of device are secured just right of the left anterior de-
scending artery and posterior descending artery, respectively, whereas
the superior part is secured to the heart along the atrioventricular groove.
The outer layer is inelastic. SCV, Superior vena cava; LA, left atrium;
ICV, inferior vena cava. (Modified from Cohn,22 Figure 2-2).
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is redundant. An access line is placed between the 2 layers to allow pressure
measurement inside the balloon lumen and to permit the injection or with-
drawal of fluid volume. Because the outer layer of the balloon is inelastic
but flexible, fluid introduced into the balloon lumen has only 1 direction of
filling space—inward toward the epicardial surface. Adjustment of luminal
balloon fluid volume changes the restraint level applied. Restraint level is
defined as the pressure measured at end diastole.
We modified the device such that the balloon would only encompass the
LVepicardium to create the partial LV restraint device (Figure 222). All de-
vices were filled with saline solution and subjected to test pressures of 200
mmHg to ensurewater tightness. Balloon luminal pressurewas recorded in
real time.
Surgical Preparation and Instrumentation
General anesthesia was induced by 6 mg/kg Telazol (Pfizer, New York,
NY) and 5% isoflurane, and maintained by 1% to 2% isoflurane. The left
external jugular vein was cannulated with a pressure central venous cath-
eter to measure CVP. Each animal was positioned supine and a median
sternotomy was performed, followed by pericardiotomy. The inferior
vena cava was dissected free and encircled with umbilical tape and snares.
The aortic root was dissected and an electromagnetic aortic flow probe
(Caroline Medical Electronics, King, NC) was placed around the aortic
root to measure aortic flow. The right femoral artery was cannulated
with a pressure transducer (Statham P10EZ transducer; SpectraMed, Ox-
ford, Calif) catheter. A high-fidelity micromanometer catheter (Millar In-
struments, Houston, Tex) was inserted in the RV through the ventricular
wall, at the level of the outflow tract, and secured with purse-string sutures.
Similarly, an 8F conductance catheter (Webster Laboratories, Baldwin
Park, Calif) and a micromanometer catheter were positioned longitudi-
nally in the LV cavity through an apical purse-string suture. The conduc-
tance catheter consisted of 5 segments; 3 to 5 segments were used to
measure ventricular volume. All electrocardiographic and hemodynamic
signals were displayed for real-time analysis and were transferred to
a minicomputer, where they were digitized at 200 Hz and stored for future
analysis.
The partial LV restraint device was then positioned to envelop the LV
completely. To secure this position, we sutured the anterior and posterior
sewing skirts of the balloon, using 3-0 interrupted Ethibond sutures (John-
son and Johnson, Somerville, NJ), to the anterior and posterior RVepicar-
dial wall. Next, the circumferential sewing skirt of the balloon was sutured
along the atrioventricular groove, between the left atrium and ventricle, us-
ing 3-0 interrupted Ethibond sutures. Care was taken to avoid the coronary
arteries (the anterior sewing skirt was secured to the RV 5 mm lateral to the
left anterior descending artery; the posterior sewing skirt was secured to the
RV 5 mm lateral to the posterior descending artery). The balloon access194 The Journal of Thoracic and Cardiovascular Surgline was then connected to a Statham P10EZ pressure transducer to mea-
sure balloon pressure in real time.
Data Collection
Volume calibration episodes were performed to calculate the volume
offset of the conductance catheter for a given data run. Twenty milliliters
of 12.5% NaCl was injected directly into the pulmonary artery via
21-guage needle to increase blood conductivity transiently while data
were recorded for approximately 10 seconds.
For each subject, all signals were recorded at 7 incrementally increased
ventricular restraint levels: 0, 3, 5, 8, 10, 12, and 14 mmHg. Data were col-
lected over 20 beats and with the ventilator off for 4 seconds to avoid respi-
ratory variations. For preload reduction, required to obtain systolic and
diastolic pressure–volume (PV) relations, umbilical tape encircling the in-
ferior vena cava was tightened for approximately 10 seconds or until peak
LV pressure fell by 50%.
Individual restraint levels were defined by the maximum pressure ap-
plied by the balloon to the LVepicardium given a constant volume of fluid
within the balloon lumen. To change restraint level, fluid was added or re-
moved from the balloon while balloon pressure was monitored in real time.
By measuring the luminal pressure within the balloon when the heart is
largest in size (end diastole), wrap tightness was quantified precisely.
Data Analysis
Data analysis was performed on a microcomputer using the computa-
tional program MATLAB (The Mathworks, Natick, Mass).
Marking beats. The beginning of ejection was defined as the point
where aortic flow first became non-0 after end diastole. The end of ejection
was identified by the point where aortic flow fell to 0 after the beginning of
ejection. End diastole was defined as the point where LV pressure began to
increase after diastole. End systole was defined at the same point as end
ejection. Hemodynamic signals were ensemble averaged over 10 beats.ery c July 2013
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FIGURE 3. Immediate effect of partial restraint therapy on pressure–vol-
ume loops. The pressure–volume loop shifts toward the right with in-
creased partial restraint therapy. LV, Left ventricle.
Mokashi et al Evolving Technology/Basic ScienceVolume calibration. Conductance catheter calibration parameters
were calculated. The volume gain (1/a) was calculated from steady-state
hemodynamic data using the aortic flow signal as a standard. The volume
offset was calculated using the data from the hypertonic saline injections.
Steady-state data. Data were recorded at steady-state baseline con-
ditions and during transient preload reduction. The steady-state data were
calculated after averaging the first 5 steady-state beats of each episode. The
following parameters were calculated: CVP, MAP, LV EDV, LV ESV,
stroke volume, and LV pressure.
Transmural pressure. The transmural myocardial pressure (Ptm)
was measured throughout the cardiac cycle. By measuring balloon luminal
pressure (PB), Ptm across the LVwall was defined as Ptm¼ PBLVpressure.
Ventricular energetics. The pressure–volume area (PVA) and
stroke work (SW) generated by the LV were calculated from a steady-
state beat according the techniques described by Suga and associates.23
The PVA is the area between the end systolic PV relationship, end diastolic
PV relationship, and the systolic portion of the PV loop, and it represents
the total mechanical work generated by the LV. The SW, or external
work, is the area within the PV loop; potential energy, or internal work,
is the portion of the PVA that lies outside the PV loop. We also calculated
transmural tension-time index (TTI), an index of MvO2, by integrating Ptm
with respect to time over the cardiac cycle.FIGURE 4. Mean aortic pressure (MAP) and central venous pressure (CVP) as
level upward of 12 mm Hg and 14 mm Hg, the MAP and CVP remain unchan
The Journal of Thoracic and CaStatistical Analysis
Mean values of parameters between groups were compared using a gen-
eral linear mixed model. Repeated-measures data were assessed using
a doubly multivariate repeated-measures design to control for the interre-
latedness of our outcomes. Statistics were performed using SPSS 13.0
(IBM, Chicago, Ill). Results with a P value .05 were considered signifi-
cant. All data are expressed as mean  standard error.
RESULTS
Incrementally higher levels of restraint were applied suc-
cessfully to the LVepicardial surface alone. The following 7
restraint levels were tested: baseline (0 mm Hg), 3 mm Hg,
5 mmHg, 8 mmHg, 10 mmHg, 12 mmHg, and 14 mmHg.
Typical PV loops with 2 separate restraint levels are shown
in Figure 3.
Systemic Hemodynamics
Systemic hemodynamics remained unchanged. There
were no significant changes from baseline in MAP and
CVP, as illustrated in Figure 4.
Indices of Left Ventricular Myocardial Oxygen
Consumption
Table 1 displays the effect of restraint levels on the fol-
lowing indices: MvO2, LV Ptm, LV TTI, PVA, and SW.
Each index was calculated for each restraint level. Left ven-
tricle Ptm decreased significantly, with the greatest decrease
occurring at higher restraint levels. Compared with base-
line, there was a significant 30% decline in LV Ptm (35.2
 3.2 mm Hg vs 23.0  0.6 mm Hg; P  .04) at a restraint
level of 10 mmHg and a 51% decrease at a restraint level of
14 mm Hg (35.2  3.2 mm Hg vs 18.0  1.1 mm Hg; P 
.03). The decrease in LV Ptm (a positive benefit) was greater
with increasing restraint levels. The LV TTI also decreased
significantly by 45% from baseline (16.5  0.8 vs 9.0 
0.3; P .01) at a restraint level of 14 mmHg (Table 1). Sim-
ilar to the LV TTI, PVA and SWeach continued to decrease
with greater restraint applied (Table 1). When compared
with baseline values, at a restraint level of 14 mm Hg, thea function of left ventricular restraint level. Despite increasing the restraint
ged.
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TABLE 1. Effect of restraint level on indices of myocardial oxygen consumption
Restraint level, mm Hg*
Transmural pressure,
mm Hgy
Tension–time index,
mm Hg/secz
Pressure–volume area,
kg/m2/sec2x
Stroke work,
mm Hg/mLjj
Baseline 35.2  3.2 16.5  0.8 3642  459 2601  679
3 31.8  1.4 15.5  0.1 3139  273 1800  416
5 28.5  1.1 14.0  0.3 2661  279 1559  304
8 25.6  1.2 12.5  0.3{ 2110  103 1445  312
10 23.0  0.6{ 11.3  0.2{ 2230  242 1252  340
12 20.5  0.9{ 10.0  0.3{ 1652  337* 1158  390*
14 18.0  1.1{ 9.0  0.3{ 1515  433* 1096  451*
Values expressed as mean  standard error. *Balloon pressure applied to left ventricle epicardial surface. yBalloon pressure less the left ventricle luminal pressure. zIndex of left
ventricle myocardial oxygen consumption. xTotal mechanical work generated by the left ventricle. jjExternal work generated by the left ventricle. {P value .05 vs baseline.
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m2/sec2 to 1515  433 kg/m2/sec2 (P  .01), and the SW
also decreased significantly by 58% from 2601  679
mm Hg/mL to 1096  451 mm Hg/mL (P  .03).
Ventricular Luminal Pressure
Figure 5 illustrates the effects of increasing LV restraint
level on LV luminal pressure. The LV luminal pressure be-
gins to increase significantly at the 10-mm Hg restraint
level. Yet, as mentioned earlier, the CVP and MAP remain
unchanged at the 14-mm Hg restraint level, and transmural
pressure continued to decrease (Figure 5).
DISCUSSION
Previously, we developed a quantitative ventricular re-
straint device to apply ventricular restraint in an adjustable
and measurable manner to both ventricles.16 A half-
ellipsoid, fluid-filled epicardial balloon is wrapped around
the ventricular epicardial surface. The fluid within serves
as the sole means of applying restraint therapy.23 With
this technique, we found that 3 mm Hg was the optimal re-
straint level at which the greatest reductions in LV Ptm andP
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FIGURE 5. Partial restraint therapy and left ventricular (LV) luminal and
transmural pressure. At the 5 to 8-mm Hg restraint level, the LV luminal
pressure begins increasing. The LV transmural pressure, however, con-
tinues to decrease significantly. *P< .05 for change from baseline. Ptm,
Transmural myocardial pressure; LVP, left ventricular chamber pressure.
196 The Journal of Thoracic and Cardiovascular SurgMvO2 indices occurred without alteration of systemic he-
modynamics.16 At a restraint level of 5 mm Hg, however,
frank cardiac tamponade developed, manifested by a de-
crease in MAP of 10 mm Hg with increased CVP. Using
an chronic ovine model of LV heart failure, we showed
that applying 3 mm Hg of restraint over a 2-month period
led to reversal of adverse LV remodeling.16
Because it was not clear whether the tamponade that oc-
curred at high restraint levels was secondary to impaired RV
or LV filling, we studied the simultaneous effect of restraint
on each ventricle.17 We found that ventricular restraint ther-
apy affects the RV and LV quite differently. Increasing the
level of restraint led to additional decreases in LV Ptm
whereas the LV diastolic compliance remained un-
changed.17 Restraint therapy on the RV, however, had
a very different effect. With greater restraint pressure, the
RV Ptm stayed the same, instead of decreasing, whereas
RV diastolic compliance decreased significantly.17 By in-
creasing the level of restraint therapy, RV filling was im-
paired.17 We concluded that restraint therapy has little or
no benefit on the RV, and indeed limits the overall therapeu-
tic efficacy of ventricular restraint therapy.
In the current study, we modified our laboratory’s quan-
titative ventricular restraint device for therapy on the LV
only. The RV was excluded. We investigated the acute ef-
fect of partial LV restraint therapy on systemic and ven-
tricular parameters in healthy sheep hearts and sheep
hearts that experienced heart failure. Each parameter
was measured and calculated as a function of restraint
level, which was increased incrementally from 0 to 14
mm Hg. Variable loaded PV loops, which help avoid the
potentially confounding effects of changes in loading con-
ditions, were used to provide load-insensitive indices of
ventricular function.
Increasing the restraint level resulted in marked de-
creases of LV MvO2 indices—specifically, LV Ptm, TTI,
PVA, and SW. Although the LV received these positive ben-
efits, MAP and CVP were not altered, even at the higher
levels of restraint applied.
With standard ventricular restraint, therapy could not be
applied at a higher level >3 mm Hg without incurringery c July 2013
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straint levels could be applied safely to the LV. In our pre-
liminary study, adverse systemic physiology did not
develop despite a 14-mm Hg restraint pressure applied
to the LV. This has the potential to lead to a much greater
benefit of therapy than that measured in standard restraint.
For example, in standard restraint, the safest maximum re-
duction in LV Ptm was 11.6%.
16 With restraint to the LV
alone, we found a reduction in LV Ptm of 52.4% at the
highest restraint level tested of 14 mm Hg. The reduction
in LV Ptm between partial and standard restraint, 52.4%
versus 11.6%, was significant (P < .001). Furthermore,
with standard restraint, the LV TTI decreased from 16.8
mm Hg/sec at baseline to 14.5 mm Hg/sec with a restraint
level of 3 mm Hg (a reduction of 13.7%).16 In the current
study with partial LV restraint, the LV TTI was decreased
safely from a baseline of 16.4 mm Hg/sec to 9.0 mm Hg/
sec at a 14-mm Hg restraint (a reduction of 45.1%). Sim-
ilarly, the reduction in LV TTI between partial and stan-
dard restraint, 45.1% versus 13.7%, was also significant
(P<.001).
Study Limitations
The current study does have several limitations. First,
this study measured the immediate effect of partial re-
straint therapy, not long-term results. Although an attrac-
tive hypothesis is that partial LV restraint would reverse
adverse LV remodeling more than conventional restraint
devices, that hypothesis remains to be tested and proved.
Long-term experiments in a chronic LV failure model
are necessary to investigate this hypothesis and, ulti-
mately, clinical trials. A second limitation of this study
is the maximum restraint level was never defined for par-
tial LV restraint. A significant increase in CVP was not
seen, nor was any significant decrease in systemic arterial
pressure from baseline seen either, which leaves the possi-
bility that even higher levels of restraint can be applied to
the LV alone with even greater benefit than that reported
here.
CONCLUSIONS
The current study substantiates the concept of partial
LV restraint in which restraint therapy is applied to the
LV alone. Our results suggest that partial LV restraint
provides beneficial effects by decreasing transmural myo-
cardial pressure, myocardial wall stress, and thus MvO2
in the acute setting. Furthermore, we documented more
therapeutic benefit at higher restraint levels than that per-
mitted by standard restraint devices. The use of partial
LV restraint may provide a more effective therapeutic op-
tion for chronic LV heart failure than standard restraint
therapy.The Journal of Thoracic and CaReferences
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